Study identifier:NIS-RCN-SYM-2012/1
ClinicalTrials.gov identifier:NCT01785901
EudraCT identifier:N/A
CTIS identifier:N/A
The asthma control rate achieved by budesonide/formoterol in clinical practice in China
asthma
-
No
-
All
1502
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Target subject population 1500 Asthma patients who have already received the treatment of budesonide/formoterol by physicians’ determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China | Other: without interventions without interventions Other Name: without interventions |